ClinicalTrials.gg

Program

AFA-281

A development code. Also written as “AFA-281 is a small molecule, orally available”.

Its studies are mostly in Alcoholism · Neuralgia · Nervous System Diseases, led by Afasci.

Furthest: phase 2, since Oct 14, 20244 company-led studies, 3 open or runningNext primary completion: Jun 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Afasci43 open or runningphase 2since Oct 14, 2024Sep 14, 2022Jun 1, 2027phase 2 · NCT06710431

Also a collaborator on its studies: cognitive-research-corporation.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2022First study: phase 1 study in NeuralgiaFirst studyNCT05547503 · 64 enrolled · United States
  2. Oct 14, 2024Phase 2 study in Nervous System DiseasesNCT06649747 · 408 planned
  3. Nov 26, 2024Phase 1 study in AlcoholismNCT06719908 · 20 planned
  4. Nov 26, 2024Phase 2 study in AlcoholismNCT06710431 · 36 planned · United States

Ahead

  1. Jun 1, 2027Primary completion: phase 2 study in AlcoholismNCT06710431
  2. Mar 31, 2032Primary completion: phase 2 study in Nervous System DiseasesNCT06649747

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06719908Alcoholism1Not yet recruitingJul 1, 202620
NCT06710431Alcoholism · United States2Not yet recruitingJun 1, 202736
NCT06649747Nervous System Diseases2Not yet recruitingMar 31, 2032408
NCT05547503Neuralgia · United States1CompletedDec 4, 202464

How it is read

Names in the registry

  • “AFA-281”, 3 entries
  • “AFA-281 is a small molecule, orally available”, 1 entry

Codes read as this program: AFA281.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
AFA-281 (Afasci): development program | ClinicalTrials.gg